The USPTO awards U.S. Patent No. 9,642,809 to Egalet covering its abuse-deterrent Guardian Technology used to create immediate-, delayed- and/or extended-release tablets for precise drug delivery of one or two different active pharmaceutical ingredients. The patent will be in effect through June 4, 2028. CEO Bob Radie says, “The newly issued patent adds to the flexibility for what we can do with future products and partnerships using our Guardian Technology. This technology puts us at an advantage to create more sophisticated delivery systems for many different kinds of pharmaceutical products.”

Egalet’s Guardian Technology

Egalet’s Guardian Technology has many applications and has been used to develop abuse-deterrent forms of commonly abused prescription medications. Egalet’s proprietary Guardian Technology is a polymer matrix tablet technology that utilizes a novel application of the well characterized manufacturing process of injection molding, which results in tablets that are hard and difficult to manipulate for misuse and abuse. This approach offers the ability to design tablets with controlled-release profiles as well as physical and chemical properties that have been demonstrated to resist both common and rigorous methods of manipulation. Tablets manufactured with Guardian Technology have been shown to have increased resistance to physical methods of manipulation, such as cutting, crushing, grinding or breaking, using a variety of mechanical and electrical tools. They are also resistant to chemical manipulation and attempts at extraction and turn into a viscous hydrogel on contact with liquid, making syringeability very difficult.